The global cancer/tumor profiling market size is expected to reach USD 21.08 billion by 2025, exhibiting a CAGR of 8.8%, according to a new report. Rising research in the application of omics sciences in cancer detection is anticipated to influence market growth.
Technological advances in biotechnology have allowed for deeper insights into metabolism and gene expression. These have accelerated the application of advanced techniques such as metabolomics and epigenetics in cancer screening and detection. Thus, demand for cancer tumor/profiling (CTP) techniques is anticipated to witness lucrative growth with the expansion of downstream applications.
Download Free Sample Pages of this report
Cancer tumor profiling is a potential procedure through which cancer can be detected and studied further to identify the stage, metabolism, and changes in morphology of the tumor. This aids in routine diagnostics as well as therapeutic decision-making. Tumor profiling has significant importance in developing therapies aimed at a specific individual, based on the severity of ailment and genomic build up of the individual.
Enhanced detection and sequencing techniques such as NGS and in-situ hybridization can help speed up the cancer tumor profiling process and are estimated to gain much traction over the coming years. Their high adoption is attributive to accelerated speed in gaining results with minimum resources and greater accuracy.
Further key findings from the report suggest:
- Personalized cancer medicine is expected to be the most lucrative application segment for CTP adoption. The segment is expected to fuel exhibit a CAGR of over 9.0%
- Owing to difference in usage of and interdependency of functional information from genomic, epigenomic, and metabolomic analysis of cancer cells, it can be expected that these technology segments will grow in tandem with each other and exhibit lucrative growth over the forecast years
- Asia Pacific is projected to witness substantial growth over the next decade owing to various developments across major economies, with increased focus of dominant players in emerging economies as well
- Key players include Illumina, Inc.; Qiagen N.V.; Neogenomics Laboratories Inc.; HTG Molecular Diagnostics, Inc.; Genomic Health Inc.; Caris Life Sciences Helomics Corporation; Nanostring Technologies; Oxford Gene Technology; Ribomed Biotechnologies, Inc.; Personal Genome Diagnostics; GenomeDX; Guardant Health; and Foundation Medicine.